Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Revolution Medicines (RVMD) Equity Average (2019 - 2025)

Revolution Medicines has reported Equity Average over the past 7 years, most recently at $1.6 billion for Q4 2025.

  • Quarterly results put Equity Average at $1.6 billion for Q4 2025, down 15.75% from a year ago — trailing twelve months through Dec 2025 was $1.6 billion (down 15.75% YoY), and the annual figure for FY2025 was $1.9 billion, down 4.76%.
  • Equity Average for Q4 2025 was $1.6 billion at Revolution Medicines, down from $1.7 billion in the prior quarter.
  • Over the last five years, Equity Average for RVMD hit a ceiling of $2.2 billion in Q1 2025 and a floor of $524.9 million in Q2 2022.
  • Median Equity Average over the past 5 years was $912.8 million (2023), compared with a mean of $1.2 billion.
  • Biggest five-year swings in Equity Average: surged 414.41% in 2021 and later dropped 25.42% in 2022.
  • Revolution Medicines' Equity Average stood at $620.4 million in 2021, then increased by 10.14% to $683.3 million in 2022, then soared by 94.91% to $1.3 billion in 2023, then surged by 43.84% to $1.9 billion in 2024, then fell by 15.75% to $1.6 billion in 2025.
  • The last three reported values for Equity Average were $1.6 billion (Q4 2025), $1.7 billion (Q3 2025), and $2.0 billion (Q2 2025) per Business Quant data.